Guangdong Hybribio Biotech Co Ltd (300639) - Net Assets
Based on the latest financial reports, Guangdong Hybribio Biotech Co Ltd (300639) has net assets worth CN¥3.72 Billion CNY (≈ $544.29 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥4.22 Billion ≈ $618.02 Million USD) and total liabilities (CN¥503.83 Million ≈ $73.73 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 300639 tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥3.72 Billion |
| % of Total Assets | 88.07% |
| Annual Growth Rate | 29.26% |
| 5-Year Change | 5.38% |
| 10-Year Change | 629.93% |
| Growth Volatility | 39.39 |
Guangdong Hybribio Biotech Co Ltd - Net Assets Trend (2012–2025)
This chart illustrates how Guangdong Hybribio Biotech Co Ltd's net assets have evolved over time, based on quarterly financial data. See 300639 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Guangdong Hybribio Biotech Co Ltd (2012–2025)
The table below shows the annual net assets of Guangdong Hybribio Biotech Co Ltd from 2012 to 2025. For live valuation and market cap data, see Guangdong Hybribio Biotech Co Ltd market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥3.66 Billion ≈ $535.84 Million |
-9.51% |
| 2024-12-31 | CN¥4.05 Billion ≈ $592.14 Million |
-20.64% |
| 2023-12-31 | CN¥5.10 Billion ≈ $746.11 Million |
-2.45% |
| 2022-12-31 | CN¥5.23 Billion ≈ $764.86 Million |
+50.41% |
| 2021-12-31 | CN¥3.48 Billion ≈ $508.50 Million |
+37.12% |
| 2020-12-31 | CN¥2.53 Billion ≈ $370.84 Million |
+113.93% |
| 2019-12-31 | CN¥1.18 Billion ≈ $173.35 Million |
+9.68% |
| 2018-12-31 | CN¥1.08 Billion ≈ $158.05 Million |
+11.25% |
| 2017-12-31 | CN¥970.90 Million ≈ $142.07 Million |
+93.54% |
| 2016-12-31 | CN¥501.67 Million ≈ $73.41 Million |
+21.26% |
| 2015-12-31 | CN¥413.71 Million ≈ $60.54 Million |
+20.05% |
| 2014-12-31 | CN¥344.60 Million ≈ $50.43 Million |
+80.06% |
| 2013-12-31 | CN¥191.38 Million ≈ $28.01 Million |
+46.89% |
| 2012-12-31 | CN¥130.29 Million ≈ $19.06 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Guangdong Hybribio Biotech Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 7300.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.33 Billion | 62.22% |
| Other Components | CN¥1.42 Billion | 37.78% |
| Total Equity | CN¥3.75 Billion | 100.00% |
Guangdong Hybribio Biotech Co Ltd Competitors by Market Cap
The table below lists competitors of Guangdong Hybribio Biotech Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Guangzhou Huayan Precision Machinery Co.Ltd.
SHE:301138
|
$505.19 Million |
|
AGI Greenpac Limited
NSE:AGI
|
$505.20 Million |
|
Just Dial Limited
NSE:JUSTDIAL
|
$505.23 Million |
|
Home Bancorp Inc
NASDAQ:HBCP
|
$505.30 Million |
|
Sumitomo Mitsui Construction Co. Ltd
F:72S
|
$505.15 Million |
|
SK Discovery Co Ltd
KO:006120
|
$505.13 Million |
|
Globalworth REIT
LSE:GWI
|
$505.07 Million |
|
Yubico AB
ST:YUBICO
|
$505.04 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Guangdong Hybribio Biotech Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,109,445,878 to 3,748,354,129, a change of -361,091,749 (-8.8%).
- Net loss of 130,942,453 reduced equity.
- Dividend payments of 3,495,681 reduced retained earnings.
- Other factors decreased equity by 226,653,616.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-130.94 Million | -3.49% |
| Dividends Paid | CN¥3.50 Million | -0.09% |
| Other Changes | CN¥-226.65 Million | -6.05% |
| Total Change | CN¥- | -8.79% |
Book Value vs Market Value Analysis
This analysis compares Guangdong Hybribio Biotech Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.92x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 16.57x to 0.92x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | CN¥0.32 | CN¥5.34 | x |
| 2013-12-31 | CN¥0.48 | CN¥5.34 | x |
| 2014-12-31 | CN¥0.82 | CN¥5.34 | x |
| 2015-12-31 | CN¥0.91 | CN¥5.34 | x |
| 2016-12-31 | CN¥1.08 | CN¥5.34 | x |
| 2017-12-31 | CN¥1.74 | CN¥5.34 | x |
| 2018-12-31 | CN¥1.60 | CN¥5.34 | x |
| 2019-12-31 | CN¥1.83 | CN¥5.34 | x |
| 2020-12-31 | CN¥3.90 | CN¥5.34 | x |
| 2021-12-31 | CN¥4.85 | CN¥5.34 | x |
| 2022-12-31 | CN¥7.45 | CN¥5.34 | x |
| 2023-12-31 | CN¥8.65 | CN¥5.34 | x |
| 2024-12-31 | CN¥6.40 | CN¥5.34 | x |
| 2025-12-31 | CN¥5.80 | CN¥5.34 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Guangdong Hybribio Biotech Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -3.49%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -19.55%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 1.11x
- Recent ROE (-3.49%) is below the historical average (12.55%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 15.14% | 14.19% | 0.82x | 1.30x | CN¥6.70 Million |
| 2013 | 15.24% | 15.96% | 0.67x | 1.42x | CN¥10.03 Million |
| 2014 | 18.42% | 24.03% | 0.68x | 1.12x | CN¥29.00 Million |
| 2015 | 15.83% | 18.91% | 0.70x | 1.20x | CN¥24.01 Million |
| 2016 | 15.55% | 19.10% | 0.69x | 1.18x | CN¥27.15 Million |
| 2017 | 9.70% | 19.46% | 0.45x | 1.11x | CN¥-2.85 Million |
| 2018 | 11.79% | 19.66% | 0.49x | 1.23x | CN¥17.33 Million |
| 2019 | 13.62% | 20.19% | 0.56x | 1.20x | CN¥39.12 Million |
| 2020 | 15.17% | 26.77% | 0.47x | 1.20x | CN¥123.61 Million |
| 2021 | 26.68% | 31.88% | 0.63x | 1.32x | CN¥532.72 Million |
| 2022 | 35.18% | 30.84% | 0.83x | 1.37x | CN¥1.24 Billion |
| 2023 | 2.89% | 12.72% | 0.19x | 1.18x | CN¥-345.66 Million |
| 2024 | -15.94% | -80.30% | 0.18x | 1.12x | CN¥-1.07 Billion |
| 2025 | -3.49% | -19.55% | 0.16x | 1.11x | CN¥-505.78 Million |
Industry Comparison
This section compares Guangdong Hybribio Biotech Co Ltd's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $1,471,930,190
- Average return on equity (ROE) among peers: 24.23%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Guangdong Hybribio Biotech Co Ltd (300639) | CN¥3.72 Billion | 15.14% | 0.14x | $505.18 Million |
| Berry Genomics Co Ltd (000710) | $41.15 Million | 36.01% | 2.32x | $406.61 Million |
| Zhejiang DiAn Diagnostics Co (300244) | $110.32 Million | 15.56% | 0.62x | $1.67 Billion |
| Hangzhou Tigermed Consulting (300347) | $146.03 Million | 32.73% | 0.28x | $4.33 Billion |
| Beijing Strong Biotechnologies Inc (300406) | $385.67 Million | 35.53% | 0.12x | $972.92 Million |
| Ningbo MedicalSystem Biotechnology Co Ltd (300439) | $2.93 Billion | 8.79% | 0.26x | $470.71 Million |
| Maccura Biotechnology Co Ltd (300463) | $6.53 Billion | 10.85% | 0.25x | $742.36 Million |
| BGI Genomics Co Ltd (300676) | $150.37 Million | 54.36% | 5.67x | $2.17 Billion |
| Amoy Diagnostics Co Ltd (300685) | $1.70 Billion | 15.35% | 0.14x | $959.68 Million |
| Shanghai Labway Clinical Laboratory Co Ltd (301060) | $1.25 Billion | 8.85% | 0.18x | $507.55 Million |
About Guangdong Hybribio Biotech Co Ltd
Guangdong Hybribio Biotech Co.,Ltd. engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes. It provides in-vitro diagnostic kits for human papilloma virus, sexually transmitted diseases (STD), thalassemia, and prenatal and postnatal. The company also offers STD real time PCR kits; hepatitis B virus real-tim… Read more